Kovid: Why the epidemic crisis in India will have a global impact on vaccines

  • By Harriet Aurel and Wijdan Mohammed Kavosa
  • BBC World Service and BBC Monitoring

photo Credit, Getty Images

image Caption,

Destroying the second wave of Kovid-19 infection in India means that the country’s largest vaccine manufacturer cannot meet the supply demand

The world’s largest vaccine manufacturer is struggling to meet the ambitious goals set for the manufacture of Kovid-19 vaccines, as India plunges into a second wave of pandemics.

The Serum Institute (SII), based in Pune, Maharashtra, Western India, was committed to leading a global effort to vaccinate vulnerable and poor people by making 100 million doses of the AstraZeneca vaccine every month.

However, with the country in crisis, the government has blocked the export of IBS reserves, thus reserving valuable vaccines for its citizens. On Tuesday, despite international pressure and several rounds of negotiations, the export of five million AstraZeneca vaccines to the UK was stopped by Narendra Modi’s government.

India’s decision to limit the export of Kovid-19 vaccines in mid-March resulted in a decrease in countries in Asia and Africa that relied heavily on its vaccines. It is not known when the export will resume completely, nor how India plans to deal with the backlog of orders.

You May Also Like

About the Author: Forrest Morton

Organizer. Zombie aficionado. Wannabe reader. Passionate writer. Twitter lover. Music scholar. Web expert.

Leave a Reply

Your email address will not be published. Required fields are marked *